A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known efficacious therapy. METHODS: In a double-blind, multinational trial, we randomly assigned 330 patients with idiopathic pulmonary fibrosis that was unresponsive to corticosteroid therapy to receive subcutaneous interferon gamma-1b or placebo. RESULTS: Over a median of 58 weeks, interferon gamma-1b therapy did not significantly affect the primary end point of progression-free survival, defined as the time to disease progression or death, and no significant treatment effect was observed on measures of lung function, gas exchange, or the quality of life. Ten percent of patients in the interferon gamma-1b group died, as compared with 17 percent of patients in the placebo group (P=0.08). Treatment with interferon gamma-1b was associated with more frequent constitutional symptoms. However, the rates of treatment adherence and premature discontinuation of treatment were similar in the two groups. More pneumonias were reported among patients in the interferon gamma-1b group, but the incidence of severe or life-threatening respiratory tract infections was similar in the two groups. CONCLUSIONS: In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life. Owing to the size and duration of the trial, a clinically significant survival benefit could not be ruled out.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, systemic administration of recombinant IFNγ (which would simulate the presence of Th1 biology) and monoclonal antibody-mediated neutralization of IL-13 (which would specifically target Th2 responses) failed to demonstrate efficacy in randomized, placebo-controlled trials of patients with IPF (141, 142).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [141]
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Nathan, C. F., Murray, H. W., Wiebe, M. E., & Rubin, B. Y. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.3.670 · Cited by 1,962
Mahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039
Editorial: Cerebral Palsy—the International Consensus Statement
Clements, R. V., & Simanowitz, A. (2000) · Clinical Risk · doi:10.1177/135626220000600401 · Cited by 856
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Self-citationinternational consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Gajewski, T. F., & Fitch, F. W. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.12.4245 · Cited by 834
Broekelmann, T. J., Limper, A. H., Colby, T. V., & McDonald, J. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6642 · Cited by 794
Research works printed but not linked: 1
- Okada T, 1993, Lymphokine Cytokine Res, 12, 87
Cited by
Items 301–400 of 649
Total Synthesis of Glycosylated Human Interferon-γ
Wang, X., Ashhurst, A. S., Dowman, L. J., Watson, E. E., Li, H. Y., Fairbanks, A. J., Larance, M., Kwan, A. H., & Payne, R. J. (2020) · Organic Letters · doi:10.1021/acs.orglett.0c02401 · Cited by 27
Idiopathic pulmonary fibrosis: an update
Dempsey, O. J., Kerr, K. M., Gomersall, L., Remmen, H., & Currie, G. P. (2006) · QJM · doi:10.1093/qjmed/hcl098 · Cited by 31
“Key histological features of IPF.”
BackgroundInfluentialA network model of correlated growth of tissue stiffening in pulmonary fibrosis
Oliveira, C. L. N., Bates, J. H. T., & Suki, B. (2014) · New Journal of Physics · doi:10.1088/1367-2630/16/6/065022 · Cited by 27
Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled
Wells, A. U. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00010006 · Cited by 27
Emerging drugs for idiopathic pulmonary fibrosis
Selman, M., Pardo, A., Richeldi, L., & Cerri, S. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.565049 · Cited by 29
“Two large placebo-controlled randomized clinical trials were then performed assessing the efficacy of IFN-g 1b in IPF patients [82,83].”
MethodDevelopment of Novel Agents for Idiopathic Pulmonary Fibrosis
O’Riordan, T. G., Smith, V., & Raghu, G. (2015) · CHEST Journal · doi:10.1378/chest.14-3218 · Cited by 29
Self-citationCurrent clinical trials for the treatment of idiopathic pulmonary fibrosis
Klingsberg, R. C., Mutsaers, S. E., & Lasky, J. A. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01672.x · Cited by 27
Normativa para la selección de pacientes candidatos a trasplante pulmonar
Román, A., Ussetti, P., Solé, A., Zurbano, F., Borro, J. M., Vaquero, J. M., de Pablo, A., Morales, P., Blanco, M., Bravo, C., et al. (2011) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2011.03.007 · Cited by 27
Lv, M., Liu, Y., Ma, S., & Yu, Z. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0111 · Cited by 28
Shi, Z., & Rockey, D. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.164863 · Cited by 26
Langenbach, S. Y., Wheaton, B. J., Fernandes, D., Jones, C., Sutherland, T. E., Wraith, B. C., Harris, T., Schuliga, M. J., McLean, C., & Stewart, A. G. (2007) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y07-065 · Cited by 26
The evolving pharmacotherapy of pulmonary fibrosis
Lota, H., & Wells, A. U. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.758250 · Cited by 25
Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis
Richeldi, L. (2012) · European Respiratory Review · doi:10.1183/09059180.00000912 · Cited by 26
Cottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.018 · Cited by 25
“Deux ECR, dont l’un a inclus plus de 800 patients atteints d’une forme non avancée de FPI, ont montré l’absence d’effet de l’interféron-!-1b sur la progression de la maladie [134] et sur la survie globale [135].”
BackgroundPulmonary Vaccination as a Novel Treatment for Lung Fibrosis
Collins, S. L., Chan‐Li, Y., Hallowell, R. W., Powell, J. D., & Horton, M. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031299 · Cited by 28
“Early clinical trials with systemic IFN-c looked promising but ultimately failed to demonstrate efficacy possible due to off target effects of systemic delivery (for example the activation of macrophages, NK cells and neutrophils) [37,41,42].”
BackgroundWang, X., Zhang, F., & Liao, L. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2021.664404 · Cited by 29
“Previous studies have also demonstrated that it was necessary to synergistically inhibit multiple pro-fibrotic cascade reactions (61, 62).”
BackgroundEsposito, I., Perna, F., Ponticiello, A., Perrella, M., Gilli, M., & Sanduzzi, A. (2005) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200501800314 · Cited by 25
Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice
Keogh, K. A., Standing, J., Kane, G. C., Terzic, A., & LIMPER, A. H. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00090204 · Cited by 27
Mikami, Y., Yamauchi, Y., Horie, M., Kase, M., Jo, T., Takizawa, H., Kohyama, T., & Nagase, T. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.10.097 · Cited by 24
Khor, Y. H., Schulte, M., Johannson, K. A., Marcoux, V. S., Fisher, J. H., Assayag, D., Manganas, H., Khalil, N., Kolb, M. R. J., Ryerson, C. J., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.02163-2022 · Cited by 25
Stephen, M. J., Emami, K., Woodburn, J. M., Chia, E., Kadlecek, S. J., Zhu, J., Pickup, S., Ishii, M., Rizi, R. R., & Rossman, M. D. (2010) · Academic Radiology · doi:10.1016/j.acra.2010.06.019 · Cited by 26
Is It Idiopathic Pulmonary Fibrosis or Not?
Salvatore, M. M., Ishikawa, G., & Padilla, M. L. (2018) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2018.01.170288 · Cited by 24
“In sarcoidosis, wheezing, which is attributed to airway-centric fibrosis is common, although patients are less symptomatic than UIP/IPF.”
MethodInfluentialUpdate in Diffuse Parenchymal Lung Disease 2006
Wells, A. U., & Hogaboam, C. M. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-052up · Cited by 25
Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches
Raghu, G. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00086606 · Cited by 28
“In fact, this new awareness of the lack of significant progression in the placebo group observed over a period of 48–72 weeks in clinical trials using IFN-c [ 17 , 24], and in the IFIGENIA study [9], is somewhat reassuring.”
MethodResultSelf-citationIdiopathic pulmonary fibrosis: Treatment update
O’Connell, O. J., Kennedy, M. P., & Henry, M. T. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0066-5 · Cited by 26
Pulmonary Fibrosis Treated with Inhaled Interferon-gamma (IFN-γ)
Fusiak, T., Smaldone, G. C., & Condos, R. (2015) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2015.1221 · Cited by 23
“IFN-c, a potent inhibitor of TGF-b offered promise as a treatment modality, but was ineffective parenterally in large clinical trials.((1,2)) However, when targeted directly to the lungs, it is a potent immunomodulator in normal subjects((10)) and patients with tuberculosis.”
BackgroundIdiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012
Raghu, G. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61256-2 · Cited by 24
Self-citationFibrocytes and the pathogenesis of diffuse parenchymal lung disease
Mehrad, B., & Strieter, R. M. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-s1-s22 · Cited by 31
“Clinical trials of interferon gamma-1b, imatinib, etanercept, sildenafil and bosentan have yielded negative results [6-12].”
BackgroundChallenges in idiopathic pulmonary fibrosis trials: the point on end-points
Albera, C. (2011) · European Respiratory Review · doi:10.1183/09059180.00001711 · Cited by 25
Chung, M. P. (2011) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2011.71.3.163 · Cited by 23
The Clinical Application of Ozonetherapy
Bocci, V. A. (2010) · Springer eBooks · doi:10.1007/978-90-481-9234-2_9 · Cited by 31
“Administration of IFN-gamma-1b in IPF patients, unresponsive to corticosteroid therapy, during about 58 weeks was practically ineffective (Raghu et al., 2004).”
BackgroundA critical assessment of treatment options for idiopathic pulmonary fibrosis.
Shah, N. R., Noble, P. W., Jackson, R. M., King, T. E., Nathan, S. D., Padilla, M. L., Raghu, G., Rhodes, M. B., Schwarz, M. I., Tino, G., et al. (2005) · PubMed · Cited by 25
Self-citationGrgic, A., Lausberg, H., Heinrich, M. C., Koenig, J., Uder, M., Sybrecht, G. W., & Wilkens, H. (2007) · Respiration · doi:10.1159/000108440 · Cited by 24
“despite very limited evidence. Treatment with interferon-γ-1b has not affected progression-free survival, pulmonary function, or quality of life [”
BackgroundTreatment of idiopathic pulmonary fibrosis: Is there anything new?
Abdelaziz, M. M., Samman, Y. S., Wali, S., & Hamad, M. M. (2005) · Respirology · doi:10.1111/j.1440-1843.2005.00712.x · Cited by 24
Challenges in pulmonary fibrosis: 7 {middle dot} Novel therapies and lung transplantation
Williams, T. J., & Wilson, J. W. (2008) · Thorax · doi:10.1136/thx.2004.031054 · Cited by 27
“44 Of the actively treated subjects, 10% died before the end of the study compared with 17% in the placebo group.”
ResultWalking the path of treatable traits in interstitial lung diseases
Amati, F., Spagnolo, P., Ryerson, C. J., Oldham, J. M., Gramegna, A., Stainer, A., Mantero, M., Sverzellati, N., Lacedonia, D., Richeldi, L., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02554-8 · Cited by 24
Immune mechanisms in fibrotic pulmonary sarcoidosis
Weeratunga, P. N., Möller, D. R., & Ho, L. (2022) · European Respiratory Review · doi:10.1183/16000617.0178-2022 · Cited by 24
Acute Exacerbations in Idiopathic Pulmonary Fibrosis
Crowley, S., Kelly, P. J., & Egan, J. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-3-200602070-00014 · Cited by 22
Johnson, W. C., & Raghu, G. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00104105 · Cited by 24
Self-citationMontesi, S. B., Gómez, C. R., Beers, M. F., Brown, R., Chattopadhyay, I., Flaherty, K. R., Garcia, C. K., Gomperts, B. N., Hariri, L. P., Hogaboam, C. M., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202307-1154ws · Cited by 21
Self-citationManagement of dyspnea in interstitial lung disease
Ryerson, C. J., Collard, H. R., & Pantilat, S. Z. (2010) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3283392b51 · Cited by 23
Current and emerging drugs for idiopathic pulmonary fibrosis
Gharaee‐Kermani, M., Hu, B., Thannickal, V. J., Phan, S. H., & Gyetko, M. R. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.4.627 · Cited by 22
The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy
Gharaee‐Kermani, M., Hu, B., Phan, S. H., & Gyetko, M. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.905 · Cited by 25
Wallaert, B., Wémeau-Stervinou, L., Salleron, J., Tillie‐Leblond, I., & Perez, T. (2012) · Pulmonary Medicine · doi:10.1155/2012/657180 · Cited by 24
Respiratory failure in interstitial lung disease
Bag, R., Suleman, N., & Guntupalli, K. K. (2004) · Current Opinion in Pulmonary Medicine · doi:10.1097/01.mcp.0000136404.09581.41 · Cited by 22
The European IPF Network: towards better care for a dreadful disease
Günther, A. (2011) · European Respiratory Journal · doi:10.1183/09031936.00012111 · Cited by 23
Khalid, I., Sherbini, N., Feteih, M. N., Wali, S., Alamoudi, O., & Al-Faifi, S. (2014) · Annals of Thoracic Medicine · doi:10.4103/1817-1737.134073 · Cited by 20
BAL Transcriptomes Characterize Idiopathic Pulmonary Fibrosis Endotypes With Prognostic Impact
Sadeleer, L. D., Verleden, S. E., Schupp, J. C., McDonough, J. E., Goos, T., Yserbyt, J., Bargagli, E., Rottoli, P., Kaminski, N., Prasse, A., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2021.12.668 · Cited by 27
Inhaled Interferon and Diffusion Capacity in Idiopathic Pulmonary Fibrosis (IPF).
Skaria, S., Yang, J., Condos, R., & Smaldone, G. C. (2015) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 28
Gax gene transfer inhibits vascular remodeling induced by adventitial inflammation in rabbits
Liu, P., Zhang, C., Zhao, Y. X., Feng, J. B., Liu, C. X., Chen, W. Q., Yao, G., Zhang, M., Wang, X. L., & Zhang, Y. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.001 · Cited by 20
Recommendations on treatment for IPF
Behr, J., & Richeldi, L. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-s1-s6 · Cited by 21
“[6] However, as this was a small study (n=330), another larger trial (INSPIRE Study), investigated the effect on overall survival in a greater number of patients (n=826).”
ResultEmerging drugs for idiopathic pulmonary fibrosis
Thannickal, V. J., Flaherty, K. R., Hyzy, R. C., & Lynch, J. P. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.4.707 · Cited by 21
Walters, T. M., Leong, M. C. H., Montesi, S. B., Ryerson, C. J., & Khor, Y. H. (2025) · European Respiratory Review · doi:10.1183/16000617.0238-2024 · Cited by 20
“Other common comorbidities affecting the ZISMAN [37] 2010 RAGHU [40] 2012 RAGHU [36] 2004 MIYAZAKI [34] 2015 MARTINEZ [41] 2014 MARTINEZ [29] 2021 RICHELDI [46] 2020 RAGHU [43] 2018 MAHER [48] 2021 BEHR [49] 2021 BEHR [42] 2016 RICHELDI [12] 2014 RICHELDI [38] 2011 KING [31] 2009 KING [10] 2014…”
Saito, A., Ichimura, Y., Kubota, N., Tanaka, R., Nakamura, Y., Fujisawa, Y., Watanabe, R., Ishitsuka, Y., Fujimoto, M., & Okiyama, N. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.09.033 · Cited by 19
Idiopathic pulmonary fibrosis and pirfenidone
Collard, H. R. (2010) · European Respiratory Journal · doi:10.1183/09031936.00006610 · Cited by 19
Spagnolo, P. (2017) · Milestones in drug therapy · doi:10.1007/978-3-0348-0977-1_11 · Cited by 18
Xue, L., Deng, D., Zheng, S., Tang, M., Yang, Z., Pei, H., Chen, Y. X., Yang, T., Liu, K., Ye, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112259 · Cited by 19
Cottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100948 · Cited by 25
Antoniou, K. M., Tzanakis, Ν., Tzortzaki, E. G., Malagari, K. S., Koutsopoulos, A. V., Alexandrakis, M. G., Wells, A. U., & Siafakas, N. M. (2008) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2008.06.005 · Cited by 18
Maximizing Deep Lung Deposition in Healthy and Fibrotic Subjects During Jet Nebulization
Samuel, J., & Smaldone, G. C. (2020) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2019.1552 · Cited by 19
The Efficiency of a Urotensin II Antagonist in an Experimental Lung Fibrosis Model
Onat, A. M., Türkbeyler, İ. H., Pehlivan, Y., Demir, T., Kaplan, D. S., Tayşi, S., Çeribaşı, A. O., Tutar, E., & Kısacık, B. (2011) · Inflammation · doi:10.1007/s10753-011-9421-6 · Cited by 18
“Some cytokines and chemokines, such as TGF-β, connective tissue growth factor, fibroblast growth factor, plateletderived growth factor, insulin-like growth factor (IGF), interleukins (IL-1, IL-10, IL-12, IL-17, IL-4, IL-13), interferon gamma, IGF-1, GM-CSF, tumor necrosis factor-alpha, and ET-1 have been investigated…”
Baroke, E., Gauldie, J., & Kolb, M. R. J. (2013) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2013.838015 · Cited by 18
Idiopathic pulmonary fibrosis: current challenges and future perspectives
Richeldi, L. (2013) · European Respiratory Review · doi:10.1183/09059180.00001413 · Cited by 18
Self-Report Daily Life Activity as a Prognostic Marker of Idiopathic Pulmonary Fibrosis
Leuchte, H. H., Mernitz, P., Baezner, C. J., Baumgartner, R., von Wulffen, W., Neurohr, C., & Behr, J. (2015) · Respiration · doi:10.1159/000441302 · Cited by 17
Erfolgreiche Rapamycin-Therapie bei idiopathischer pulmonaler Fibrose (IPF) im Pr�finalstadium
Buschhausen, L., Kamm, M., Arns, W., Schulze-Lohoff, E., & Weber, M. F. A. (2005) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-005-1015-3 · Cited by 17
“an 330 Patienten nicht bestätigt werden [9].”
BackgroundThe Elusive Goal of Therapy for Usual Interstitial Pneumonia
Teirstein, A. S. (2004) · New England Journal of Medicine · doi:10.1056/nejme038182 · Cited by 19
Raghu, G. (2009) · CHEST Journal · doi:10.1378/chest.09-0848 · Cited by 18
Self-citationIdiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective
Tu, H., Han, L. W., Hsu, J. C., Kamath, N., & Pan, L. (2023) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666231181537 · Cited by 17
SHP2 : The protein tyrosine phosphatase involved in chronic pulmonary inflammation and fibrosis
Chang, C., Lin, C., Chen, B.-C., Lin, P., & Chen, C. (2021) · IUBMB Life · doi:10.1002/iub.2559 · Cited by 18
“38–40 Extensive clinical trials reveal a trend toward lower mortality in IFN-γ-1b-treated patients compared with placebo-treated patients.(41,42) However, an opposite finding provided by the other randomized clinical trial of IFN-γ-1b (INSPIRE, NCT00075998) indicates the absence of protective benefits in IPF patients…”
ResultSurgical biopsy: its appropriateness in diagnosing interstitial lung disease
Riley, D. J., & Costanzo, E. J. (2006) · Current Opinion in Pulmonary Medicine · doi:10.1097/01.mcp.0000239549.70573.d9 · Cited by 16
Olson, A. L., Yunt, Z. X., & Swigris, J. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00006-9 · Cited by 16
Pulmonary fibrosis, part II: state-of-the-art patient management
Meyer, K. C. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1312347 · Cited by 18
“Subsequently, a considerable number of high-quality, placebocontrolled, RCTs have been conducted over the past 15 years with many agents that appeared to have potential benefit in pre-clinical investigations (9-25).”
BackgroundIdiopathic pulmonary fibrosis: present understanding and future options
du Bois, R. M. (2011) · European Respiratory Review · doi:10.1183/09059180.00001511 · Cited by 16
Clinical trials and tribulations--lessons from pulmonary fibrosis
Olson, A. L., Swigris, J. J., & Brown, K. K. (2012) · QJM · doi:10.1093/qjmed/hcs066 · Cited by 15
Self-citationBehr, J., Nathan, S. D., Costabel, U., Albera, C., Wuyts, W. A., Glassberg, M. K., Haller, H., Alvaro, G., Gilberg, F., Samara, K. D., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02565-3 · Cited by 22
Paediatric interstitial lung disease
Bush, A. (2005) · Breathe · doi:10.1183/18106838.0201.16 · Cited by 15
New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases?
Rogler, G. (2014) · Digestive Diseases · doi:10.1159/000367825 · Cited by 15
Therapeutic Update in Idiopathic Pulmonary Fibrosis
Chan, A. L., Rafii, R., Louie, S., & Albertson, T. E. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8244-9 · Cited by 16
“progression-free survival (defined as death or a categorical change in pre-defined pulmonary function values) over a 58-week period [22].”
BackgroundSyndrome d'emphysème des sommets et fibrose pulmonaire des bases combinés
Cottin, V., Brillet, P., Nunès, H., & Cordier, J.-F. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2007.03.005 · Cited by 15
Guidelines for the Selection of Lung Transplantation Candidates
Román, A., Ussetti, P., Solé, A., Zurbano, F., Borro, J. M., Vaquero, J. M., de Pablo, A., Morales, P., Blanco, M., Bravo, C., et al. (2011) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2011.03.002 · Cited by 18
Fibrosis pulmonar idiopática: en busca de un tratamiento eficaz
Selman, M., Navarro, C., & Gaxiola, M. (2005) · Archivos de Bronconeumología · doi:10.1016/s0300-2896(05)70763-8 · Cited by 17
Martínez, J. A. B., Ferreira, J. C., Tanni, S. É., Alves, L. R., Cabral, B. F., de Carvalho, C. R. R., Cezare, T. J., da Costa, C. H., Gazzana, M. B., Jezler, S. F. D. O., et al. (2020) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20190423 · Cited by 18
Paediatric interstitial lung disease: not just kid's stuff
Bush, A. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00081704 · Cited by 15
“Modern ILD treatment is not just "steroids for everything"; new cytokinebased therapies, such as interferon c-1b for fibrosing alveolitis [ 35 ], GM-CSF for adult-onset PAP [16] and anti-tumour necrosis factor-a receptor blockers for sarcoidosis [36], herald a new era of treatment.”
BackgroundHadi, D. D., Marsool, M. D. M., Marsool, A. D. M., Vora, N., Al‐Badri, S. G., Al‐Fatlawi, N., Wssawi, A. F. A. A., Al‐Ibraheem, A. M. T., Hamza, K. A., Prajjwal, P., et al. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.1079 · Cited by 16
Management of patients with fibrosing interstitial lung diseases
Morrow, L. E., Hilleman, D. E., & Malesker, M. A. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab375 · Cited by 15
“in 330 patients with IPF from 58 centers in the United States, Europe, Canada, and South Africa.(35) This study randomized patients to IFN (200 μg subcutaneously 3 times weekly, n = 162) or placebo (n = 68) for 52 weeks.”
BackgroundHealth-related quality of life does not predict mortality in idiopathic pulmonary fibrosis.
Nishiyama, O., Taniguchi, H., Kondoh, Y., Kimura, T., Kataoka, K., Nishimura, K., Ogawa, T., Watanabe, F., Arizono, S., & Tohda, Y. (2012) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 15
A Clinicianʼs Guide to the Diagnosis and Treatment of Interstitial Lung Diseases
Danoff, S. K., Terry, P. B., & Horton, M. R. (2007) · Southern Medical Journal · doi:10.1097/smj.0b013e3180485c62 · Cited by 16
“In addition, although demonstrating promising results in a small phase II trial, interferongamma has recently been shown to be ineffective in altering disease progression or mortality in a large multinational clinical trial.(36,37) However, subgroup analysis from that trial did suggest a potential benefit of the drug…”
ResultAvdeev, S. N. (2015) · PULMONOLOGIYA · doi:10.18093/0869-0189-2015-25-5-600-612 · Cited by 15
Pharmacological Treatment of Fibrosis: a Systematic Review of Clinical Trials
Siani, A. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00292-2 · Cited by 14
“[63] Subcutaneous IFN-γ 1b in IPF patients No improvement in lung function, gas exchange, and quality of life.”
BackgroundResultSantoleri, F., Auriemma, L., Spacone, A., Marinari, S., Esposito, F., Vita, F. D., Petragnani, G., Fabio, C. D., Fabio, L. D., & Costantini, A. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211008625 · Cited by 14
G protein-coupled receptor 56 regulates matrix production and motility of lung fibroblasts
Yang, J., Wang, Z., Leng, D., Dai, H., Wang, J., Liang, J., Jiang, D., & Wang, C. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214529395 · Cited by 13
Minimal clinically important difference in idiopathic pulmonary fibrosis
Kang, M., Marts, L. T., Kempker, J. A., & Veeraraghavan, S. (2021) · Breathe · doi:10.1183/20734735.0345-2020 · Cited by 17
Gümüştaş, S., Inan, N., Akansel, G., Başyïğït, I., & Cïftçi, E. (2013) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 28
Road ahead to respiratory health: Experts chart future research directions
Heffner, J. E., Holgate, S. T., Chung, K. F., Niederman, M. S., Daley, C. L., Jett, J. R., Stradling, J. R., Wells, A. U., Light, R. W., Tapson, V. F., et al. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01484.x · Cited by 13
Miyazaki, Y., Azuma, A., Inase, N., Taniguchi, H., Ogura, T., Inoue, E., Takeuchi, M., Yoshizawa, Y., Sugiyama, Y., & Kudoh, S. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.05.002 · Cited by 13
“[17] Raghu G, Brown KK, Bradford WZ, et al.”
BackgroundResultAerobic Exercise Attenuated Bleomycin-Induced Lung Fibrosis in Th2-Dominant Mice
Andrade-Sousa, A. S., Pereira, P. R., MacKenzie, B., Oliveira‐Junior, M. C., Neto, E. A., Brandão-Rangel, M. A. R., Damaceno‐Rodrigues, N. R., Caldini, E. T. E. G., Velosa, A. P. P., Teodoro, W. R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163420 · Cited by 13
Assayag, D., Vittinghoff, E., Ryerson, C. J., Cocconcelli, E., Tonelli, R., Hu, X., Elicker, B. M., Golden, J. A., Jones, K. D., King, T. E., et al. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.06.012 · Cited by 14
Self-citationDecreased Apoptotic Rate of Alveolar Macrophages of Patients with Idiopathic Pulmonary Fibrosis
Drakopanagiotakis, F., Xifteri, A., Tsiambas, E., Karameris, A., Tsakanika, K., Karagiannidis, N., Mermigkis, D., Polychronopoulos, V., & Bouros, D. (2012) · Pulmonary Medicine · doi:10.1155/2012/981730 · Cited by 13
Endothelin receptor antagonists – their role in pulmonary medicine
Boniface, S., & Reynaud‐Gaubert, M. (2011) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2009.07.001 · Cited by 12
Elevated sL1 ‐ CAM levels in BALF and serum of IPF patients
Zhang, Y., Bi, L., Qiu, Y., Wang, Y., Ding, J., Zhuang, Y., Tian, Y., & Cai, H. (2015) · Respirology · doi:10.1111/resp.12659 · Cited by 13
Metadata
- Authors
- Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E.
- Affiliations
- University of Washington (US)
- National Jewish Health (US)
- Yale University (US)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-01-08
- Volume
- 350
- Issue
- 2
- Pages
- 125-133
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2108226118
- Cited by
- 652
- References
- 34
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 8 · 2023: 15 · 2022: 15 · 2021: 16 · 2020: 15 · 2019: 17 · 2018: 11 · 2017: 22 · 2016: 21 · 2015: 29 · 2014: 20 · 2013: 38 · 2012: 39
- FWCI
- 54.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, interferon gamma-1b, progression-free survival, corticosteroid-refractory disease, lung function, quality of life, mortality, pneumonia, constitutional symptoms, medication adherence
- MeSH terms
- Double-Blind Method, Female, Humans, Injections, Subcutaneous, Interferon-gamma, Male, Middle Aged, Pulmonary Fibrosis, Recombinant Proteins, Respiratory Function Tests, Respiratory Tract Infections, Risk, Proportional Hazards Models, Treatment Failure, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.